The Valley Desk

NCT04392154 · Interventional trial

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

Overall registry status Completed

Phase 3

Conditions Atopic Dermatitis

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov